Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan in EGFR-Mutated NSCLC (AndroMETa-Lung-713)
NCT07155187Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2025
- Primary completion
- Sep 2030
- Countries
- 20
01
Overview
A Phase 3 trial of telisotuzumab adizutecan in non-small cell lung cancer (NSCLC), sponsored by AbbVie Inc.. Started Dec 2025; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07155187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07155187.